大股东反对，超10亿元定增“黄了”，盟科药业需妥善解决内部矛盾

Core Viewpoint - Amgen Pharmaceutical has terminated its private placement plan with Haiqing Pharmaceutical, reflecting internal shareholder disputes and deeper challenges in its development path [2][3] Group 1: Termination of Private Placement - The private placement plan aimed to issue approximately 164 million A-shares to Haiqing Pharmaceutical, raising 1.033 billion yuan, which would have made Haiqing the controlling shareholder [2] - Despite over 80% approval at the temporary shareholders' meeting on October 9, the board decided to terminate the plan, citing potential impacts on the company's stable operations [2] Group 2: Internal Governance Challenges - The company lacks a controlling shareholder and actual controller, leading to difficulties in quickly coordinating interests and opinions among shareholders [2] - The opposition from the largest shareholder, Genie Pharma, not only questioned the private placement plan but also hinted at a struggle for control and future direction of the company [2] Group 3: Product Performance and Financial Challenges - The core product, Contizolam, has not achieved sales exceeding 100 million yuan since its launch in 2021, facing slow market growth due to strict management regulations and intense competition [3] - The company has accumulated losses exceeding 1.3 billion yuan over the past four years, with profitability remaining a critical issue despite some recovery in the first three quarters of this year [3] Group 4: Future Opportunities and Strategies - The company has the potential to enhance its market competitiveness by advancing its multi-product pipeline in the anti-infection field [3] - Strengthening communication and coordination among shareholders, establishing a more transparent decision-making mechanism, and seeking strategic investor partnerships are essential for improving market penetration and accelerating new product launches [3]